# Neukio Biotherapeutics Co

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neukio-biotherapeutics-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.neukio.com
- Total disclosed funding: $90M
- Latest round: Series A (Sep 2, 2022)
- Investors on record: 6

## About

Based in Shanghai, China, and established in 2021, Neukio Biotherapeutics Co, Ltd. operates as a biopharmaceutical company that focuses on the development of allogeneic cell therapy for tumors. Richard Liqun Wang, the company's founder, served as CEO of Fosun Kite Biotech, and completed the commercialization of CAR-T products in less than three years. Moreover, it is equipped with 60,000 square meters of R&D and manufacturing centre. 

Neukio Biotherapeutics Co, Ltd. engages in the R&D of cell immune therapy for tumors based on modular and genetic technologies. The cell pipeline includes natural killer cells (Nk), and induced pluripotent stem cells (iPSC).

## Funding rounds

- Series A, Sep 2, 2022, $50M — IDG Capital, Lilly Asia Ventures, CD Capital, Alwin Capital, Sherpa Healthcare Partners, Kuanyu Capital
- Angel, Jul 29, 2021, $40M — IDG Capital, Lilly Asia Ventures, Sherpa Healthcare Partners

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Angel, Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Angel, Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Angel, Series A
- CD Capital — Series A
- Alwin Capital — Series A
- Kuanyu Capital (https://capitalatlas.ai/funds/kuanyu-capital) — Series A